Sonoma Pharmaceuticals (SNOA) Stock: Buy, Sell, or Hold?
SNOA - Sonoma Pharmaceuticals, Inc. Common Stock
$1.24
-0.01 (-1.20%)
▼
5d:
-2.76%
30d:
-4.26%
90d:
-1.2%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SNOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SNOA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SNOA is currently trading at $1.24, which is considered oversold relative to its 30-day fair value range of $1.25 to $1.33.
Technical Outlook: Technically, SNOA is in a uptrend. The price is currently testing key support at $1.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+860.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNOA is in a uptrend. The price is currently testing key support at $1.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.00 (+860.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.25 -
$1.33
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 860.0% below Wall St target ($12.00)
- NEUTRAL: Bottoming setup forming (46/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.33
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.20
Resistance Level
$1.31
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.23
Wall Street Target
$12.00
(+860.0%)
Revenue Growth (YoY)
59.6%
Profit Margin
-10.3%
Share & Embed Analysis
Last updated: October 02, 2026 2:37 PM ET
Data refreshes hourly during market hours. Next update: 3:37 PM
Data refreshes hourly during market hours. Next update: 3:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
